• Thermo Fisher Scientific Inc. will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 8:30 a.m. (EDT).
• Casper, chairman, president, and CEO, will present at the conference.
• The presentation will be available via the Investors section of Thermo Fisher Scientific's website.
• Thermo Fisher Scientific is a world leader in serving science.
WALTHAM, Mass. / Aug 28, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 8:30 a.m. (EDT).
You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
| Last Trade: | US$613.57 |
| Daily Change: | 2.40 0.39 |
| Daily Volume: | 567,444 |
| Market Cap: | US$234.380B |
June 03, 2024 April 24, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
